Amendments to the Claims

1. (Currently amended) A method of inducing a T_H1 polarized immune response to an antigen, comprising parenterally administering to a subject microparticles sized such that at least 50% of the microparticles are greater than ~~at least~~ 0.6 μm and at least 50% of the microparticles are less than 5 μm, the microparticles comprising said antigen entrapped or encapsulated by a biodegradable polymer.

2. (Original) The method of Claim 1, wherein the microparticles are sized such that at least 50% of the microparticles are less than 3 μm.

3. (Original) The method of Claim 1, wherein the biodegradable polymer comprises a copolymer of lactic acid and glycolic acid or enantiomers thereof.

4. (Original) The method of Claim 1, wherein the microparticles are formed using a solvent evaporation method.

5. (Original) The method of Claim 1, wherein the antigen comprises a *B. pertussis* antigen.

6. (Original) The method of Claim 1, wherein the parenteral administration is selected from the group consisting of intraperitoneal administration, subcutaneous administration and intramuscular administration.

Claims 7 to 14 have been cancelled.

15. (Currently amended) A vaccine formulation for enhancing the T_H1 immune response to at least one antigen and adapted for parenteral administration comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of

microparticles sized such that at least 50% of the microparticles are greater than ~~at least~~ 0.6 μm and at least 50% of the microparticles are less than 5 μm, the microparticles comprising said antigen entrapped or encapsulated by a biodegradable polymer.

16. (Original) The vaccine formulation of Claim 15, wherein the microparticles are sized such that at least 50% of the microparticles are less than 3 μm.

17. (Original) The vaccine formulation of Claim 15, wherein the biodegradable polymer comprises a copolymer of lactic acid and glycolic acid or enantiomers thereof.

18. (Original) The vaccine formulation of Claim 15, wherein the microparticles are formed using a solvent evaporation method.

19. (Original) The vaccine formulation of Claim 15, wherein the antigen comprises a *B. pertussis* antigen.

20. (Original) The vaccine formulation of Claim 15, wherein the microparticles comprise at least 2 subpopulations of microparticles, each subpopulation comprising a different antigen entrapped or encapsulated by a biodegradable polymer.

Claims 21 to 34 have been cancelled.

35. (New) The method of Claim 1, wherein the microparticles are sized such that the average diameter of the microparticles is from about 2.2 μm to about 4.3 μm.

36. (New) The method of Claim 35, wherein the microparticles are sized such that at least 50% of the microparticles are less than 3 μm.

37. (New) The method of Claim 35, wherein the biodegradable polymer comprises a copolymer of lactic acid and glycolic acid or enantiomers thereof.

38. (New) The method of Claim 35, wherein the microparticles are formed using a solvent evaporation method.

39. (New) The method of Claim 35, wherein the antigen comprises a *B. pertussis* antigen.

40. (New) The method of Claim 35, wherein the parenteral administration is selected from the group consisting of intraperitoneal administration, subcutaneous administration and intramuscular administration.

41. (New) The vaccine formulation of Claim 15, wherein the microparticles are sized such that the average diameter of the microparticles is from about 2.2 μm to about 4.3 μm.

42. (New) The vaccine formulation of Claim 41, wherein the microparticles are sized such that at least 50% of the microparticles are less than 3 μm.

43. (New) The vaccine formulation of Claim 41, wherein the biodegradable polymer comprises a copolymer of lactic acid and glycolic acid or enantiomers thereof.

44. (New) The vaccine formulation of Claim 41, wherein the microparticles are formed using a solvent evaporation method.

45. (New) The vaccine formulation of Claim 41, wherein the antigen comprises a *B. pertussis* antigen.

46. (New) The vaccine formulation of Claim 41, wherein the microparticles comprise at least 2 subpopulations of microparticles, each subpopulation comprising a different antigen entrapped or encapsulated by a biodegradable polymer.